However, in the first clinical trial of its kind in RA patients to employ a specific MEK SMI, ARRY-162, used in combination with a stable dose of methotrexate, none of the ARRY-162 treatment groups demonstrated a significant ACR20 response compared to placebo after 12 wks [84]. The gene discussed is MAP2K7; the disease is rheumatoid arthritis.